Thyroid News and Research RSS Feed - Thyroid News and Research

Adult survivors of childhood cancer at risk for pituitary hormone deficiencies

Adult survivors of childhood cancer at risk for pituitary hormone deficiencies

Decades after undergoing cranial irradiation for childhood cancer, St. Jude Children's Research Hospital investigators found that adult survivors of pediatric cancer remain at risk for pituitary hormone deficiencies that may diminish their health and quality of life. [More]
Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Eisai Inc. announced today that the U.S. Food and Drug Administration approved the company's receptor tyrosine kinase inhibitor LENVIMA (lenvatinib) for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC). [More]
Lenvatinib trial offers hope for thyroid cancer patients

Lenvatinib trial offers hope for thyroid cancer patients

A new targeted therapy called lenvatinib has been shown to improve progression-free survival among patients with advanced thyroid cancer that is not responsive to iodine-131. [More]
Lenvatinib therapy improves survival in patients with advanced radioiodine-refractory thyroid cancer

Lenvatinib therapy improves survival in patients with advanced radioiodine-refractory thyroid cancer

In a pivotal Phase III study led by researchers at The University of Texas MD Anderson Cancer Center, the oral anti-angiogenic therapy lenvatinib has shown dramatic improvement in progression-free survival in patients with advanced radioiodine-refractory thyroid cancer. [More]
ATA recommends daily serving of iodine in multivitamin/mineral supplements for pregnant, breastfeeding women

ATA recommends daily serving of iodine in multivitamin/mineral supplements for pregnant, breastfeeding women

The American Thyroid Association has championed the effort to include a daily serving of iodine in multivitamin/mineral supplements intended for pregnant and breastfeeding women, and it applauds the new guidelines released by the U.S. Council for Responsible Nutrition advising manufacturers to include 150 micrograms of iodine to these daily supplements. [More]
Combination therapies may overcome resistance to targeted cancer drugs

Combination therapies may overcome resistance to targeted cancer drugs

A protein called YAP, which drives the growth of organs during development and regulates their size in adulthood, plays a key role in the emergence of resistance to targeted cancer therapies, according to a new study led by UC San Francisco researchers. [More]
Genomics of papillary thyroid carcinoma (PTC): an interview with Professor Thomas J. Giordano

Genomics of papillary thyroid carcinoma (PTC): an interview with Professor Thomas J. Giordano

There are two types of thyroid cells and therefore there are two broad types of thyroid cancer. Medullary carcinoma is derived from parafollicular or C cells, whereas follicular cells give rise to several types of thyroid cancers. [More]
Thyroid disease can affect woman's reproductive health

Thyroid disease can affect woman's reproductive health

Thyroid disease can have significant effects on a woman's reproductive health and screening for women presenting with fertility problems and recurrent early pregnancy loss should be considered, suggests a new review published today (23 January) in The Obstetrician & Gynaecologist. [More]
Physicians in subspecialties report increased satisfaction with concierge medicine model

Physicians in subspecialties report increased satisfaction with concierge medicine model

Attracted to the opportunity to provide concierge medicine's hallmark model of personalized care, physicians in subspecialties such as cardiology, endocrinology, pulmonology, and others are increasingly converting their practices, and reporting increased professional and personal satisfaction, according to Michael Friedlander, Principal at national healthcare consulting firm Specialdocs. [More]
Study: Iodine deficiency during pregnancy can impair child's intellectual development

Study: Iodine deficiency during pregnancy can impair child's intellectual development

Pregnant women in Austria commonly suffer from an iodine deficiency. This may have a negative impact on the development of their unborn child's brain. These are the key findings of a joint study by the Endocrinology and Metabolism Unit at the University Department of Internal Medicine III together with the University Department of Gynaecology at the MedUni Vienna and AGES, which have now been published in the European Journal of Clinical Nutrition. [More]
Research findings may lead to new treatment for hypothyroidism

Research findings may lead to new treatment for hypothyroidism

An international research team led by physician-scientists at Rush University Medical Center have gained new insights into hypothyroidism - a condition affecting about 10 million people in the U.S. - that may lead to new treatment protocols for the disease, particularly among the approximately 15 percent of patients for whom standard treatments are less effective. [More]
Low alcohol consumption, plant-based diet reduce risk of obesity-related cancers

Low alcohol consumption, plant-based diet reduce risk of obesity-related cancers

Low alcohol consumption and a plant-based diet, both healthy habits aligning with current cancer prevention guidelines, are associated with reducing the risk of obesity-related cancers, a New York University study shows. [More]
ANSTO launches nuclear medicine program to improve diagnosis, treatment of cancer and heart disease

ANSTO launches nuclear medicine program to improve diagnosis, treatment of cancer and heart disease

You can’t see it, hear it or smell it, and it’s constantly changing: but despite that, Australia’s nuclear scientists have figured out how to more accurately measure the unit of activity for radionuclides, the Becquerel (Bq). [More]
FDA approves Novo Nordisk’s weight loss injection, Saxenda

FDA approves Novo Nordisk’s weight loss injection, Saxenda

Novo Nordisk today announced that the Food and Drug Administration (FDA) has approved the new drug application (NDA) for Saxenda® (liraglutide [rDNA origin] injection), the first once-daily glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management. [More]
Progression to combined pituitary hormone deficiency common in IGHD

Progression to combined pituitary hormone deficiency common in IGHD

Researchers have found that a high proportion of children initially diagnosed with isolated growth hormone deficiency will progress to combined pituitary hormone deficiency. [More]
Novartis announces FDA approval of Signifor LAR for treatment of patients with acromegaly

Novartis announces FDA approval of Signifor LAR for treatment of patients with acromegaly

Novartis announced today that the US Food and Drug Administration has approved Signifor long-acting release (LAR) (pasireotide) for injectable suspension, for intramuscular use, for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. [More]
New Cancer Council data finds fivefold increase in thyroid cancer rates

New Cancer Council data finds fivefold increase in thyroid cancer rates

New Cancer Council data has found a fivefold increase in rates of thyroid during the past 30 years in Queensland, with nearly 500 Queenslanders diagnosed in 2012 compared to less than 50 diagnoses in 1982. [More]
Vaccinex completes VX15/2503 Phase 1 clinical trial in patients with advanced, refractory solid tumors

Vaccinex completes VX15/2503 Phase 1 clinical trial in patients with advanced, refractory solid tumors

Vaccinex, Inc. today announced the successful completion of a multicenter Phase 1, multiple ascending dose clinical trial of VX15/2503 anti-Semaphorin 4D (SEMA4D) antibody in 42 adult patients with advanced, refractory solid tumors. [More]
Endocrine disrupting chemicals can alter thyroid levels in pregnant women, may affect fetus

Endocrine disrupting chemicals can alter thyroid levels in pregnant women, may affect fetus

A new study led by biologist R. Thomas Zoeller of the University of Massachusetts Amherst provides "the strongest evidence to date" that endocrine disrupting chemicals such as polychlorinated biphenyls (PCB) found in flame retardant cloth, paint, adhesives and electrical transformers, can interfere with thyroid hormone action in pregnant women and may travel across the placenta to affect the fetus. [More]
Mercy Medical Center partners with Everseat to employ new scheduling platform for Women's Services

Mercy Medical Center partners with Everseat to employ new scheduling platform for Women's Services

Mercy Medical Center has announced that it has entered into an agreement with Everseat to employ an all new mobile scheduling platform for its Women's Services, including: Gynecology, Gynecologic Oncology, Breast Disease and Breast Cancer, Imaging Services such as mammograms, and Endocrinology, including diabetes, thyroid and bone health. [More]
Advertisement